Journal of Neurology

, Volume 251, Issue 11, pp 1297–1303

Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis

REVIEW

Abstract

This review explores the salient issues surrounding liver injury and liver monitoring associated with beta-interferon (IFNB) treatment for multiple sclerosis (MS). Post-marketing studies have found a higher proportion of IFNB-treated MS patients with elevated aminotransferases than reported in the pivotal clinical trials. Although the risk of severe liver injury appears small, the true incidence is unknown. Post-marketing studies have shown that the greatest period of risk for the development of liver test abnormalities appears to be in the first year of IFNB treatment. The risk also increases with the more frequently administered, higher-dosage IFNBs. Males are more likely than females to develop elevated aminotransferases (> upper normal limit), although females appear at a greater risk of severe liver injury. Of the commonly used biochemical liver tests, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP) and bilirubin appear the most useful for routine monitoring of IFNB treatment. Whilst many other factors can affect liver test results, including obesity, alcohol, concomitant medications, co-morbidities and theoretically even MS itself, regular liver testing both prior and during IFNB therapy might help minimise Type A or dose/frequency dependent aminotransferase elevations. However, testing will probably not prevent the Type B idiosyncratic reactions which can result in severe hepatic injury; hence patients need to be aware, and to report hepatic side effects promptly.

Key words

multiple sclerosis beta-interferon hepatic injury aminotransferases adverse drug reactions 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ferguson J, Sandrock A (2003) Important New Prescribing Information. http://www.fda.gov/medwatch/SAFET Y/2003/avonex_deardoc.pdf (Accessed 16 Dec 2003)Google Scholar
  2. 2.
    Gehshan A, Ruebig A, Salesse M (2003) Important new safety information: Hepatic injury associated with beta-interferon treatment for Multiple Sclerosis http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/beta-interferon_hpc_e.pdf (Accessed 16 Dec 2003)Google Scholar
  3. 3.
    CDER-PHRMA-AASLD (2000) Drug-induced hepatotoxicity White Paper Postmarketing Considerations. http:www//fda.gov/cder/livertox/postmarket.pdf (Accessed 28 July 2003)Google Scholar
  4. 4.
    Lewis JA (1981) Post-marketing surveillance—how many patients? Trends Pharmacol Sci 2:93–94Google Scholar
  5. 5.
    Rawlins MD (1988) Spontaneous reporting of adverse drug reactions I: The data. Br J Clin Pharmacol 26:1–5PubMedGoogle Scholar
  6. 6.
    Zakim D, Boyer T (1996) Hepatology: A textbook of liver disease (London, Saunders)Google Scholar
  7. 7.
    CDER-PHRMA-AASLD (2000) Drug-induced Hepatotoxicity. Clinical White Paper. http:www//fda.gov/cder/livertox/clinical.pdf (Accessed July 28th 2003)Google Scholar
  8. 8.
    Kaplan MM (2002) Alanine aminotransferase levels: what’s normal? Ann Intern Med 137:49–51PubMedGoogle Scholar
  9. 9.
    Pratt DS, Kaplan MM (2000) Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients. N Engl J Med 342:1266–1271PubMedGoogle Scholar
  10. 10.
    Kew M (2000) Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 355:591–592PubMedGoogle Scholar
  11. 11.
    Dufour DR (2000) Laboratory guidelines for screening, diagnosis and monitoring of hepatic injury. Washington, D. C., USA: National Academy of Clinical BiochemistryGoogle Scholar
  12. 12.
    Minuk GY (1998) Canadian Association of Gastroenterology Practice Guidelines: Evaluation of abnormal liver enzyme tests. Can J Gastroenterol 12:417–421PubMedGoogle Scholar
  13. 13.
    Crispe I (1999) T lymphocytes in the Liver. Wiley-Liss, New YorkGoogle Scholar
  14. 14.
    Dobin NB, Switzer JL (1954) Liver function and other blood chemistry tests in multiple sclerosis. AMA Arch Neurol Psych 71:405–424Google Scholar
  15. 15.
    Kojima H, Uemura M, Sakurai S, Ann T, Ishii Y, Imazu H, Yoshikawa M, Ichijima K, Fukui H (2002) Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol 37:617–625PubMedGoogle Scholar
  16. 16.
    Thompson P Jr, Strum D, Boehm T, Wartofsky L (1978) Abnormalities of liver function tests in tyrotoxicosis. Mil Med 143:548–551PubMedGoogle Scholar
  17. 17.
    Nunez-Martinez O, Alvarez E, Clemente G, Rodriguez-Mahuo M, de Andres C (2003) Autoimmune hepatitis and multiple sclerosis P161. Mult Scler 9:S34–S35Google Scholar
  18. 18.
    Pontecorvo MJ, Levinson JD, Roth JA (1992) A patient with primary biliary cirrhosis and multiple sclerosis. Am J Med 92:433–436PubMedGoogle Scholar
  19. 19.
    Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN (2002) Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum 46:1851–1856PubMedGoogle Scholar
  20. 20.
    Sadovnick AD, Paty DW (1989) Concurrence of Multiple Sclerosis and Inflammatory bowel disease. N Engl J Med 321:762–763Google Scholar
  21. 21.
    Renton KW (2001) Alterations of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147–163PubMedGoogle Scholar
  22. 22.
    Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meche FG, van Doorn PA, Hintzen RQ (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125:952–960PubMedGoogle Scholar
  23. 23.
    Stricker B (1992) Drug-Induced Hepatic Injury, 2nd edn. Elsevier, AmsterdamGoogle Scholar
  24. 24.
    Tremlett HL, Wiles CM, Luscombe DK (2001) Prescribing for MS patients in General Practice: a case control study. J Clin Pharm Ther 26:437–444PubMedGoogle Scholar
  25. 25.
    Larrey D (2000) Drug-induced liver diseases. J Hepatol 32:77–88PubMedGoogle Scholar
  26. 26.
    Sterling MJ, Kane M, Grace ND (1996) Pemoline-induced autoimmune hepatitis. Am J Gastroenterol 91:2233–2234PubMedGoogle Scholar
  27. 27.
    Chan CH (1990) Dantrolene sodium and hepatic injury. Neurology 40:1427–1432PubMedGoogle Scholar
  28. 28.
    Lapierre Y, Bouchard S, Tansey C, Gendron D, Barkas WJ, Francis GS (1987) Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 14:513–517PubMedGoogle Scholar
  29. 29.
    Schattner A, Von der Walde J, Kozak N, Sokolovskaya N, Knobler H (1999) Nitrofurantoin-induced immune-mediated lung and liver disease. Am J Med Sci 317:336–340CrossRefPubMedGoogle Scholar
  30. 30.
    Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L (1991) Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 32:715–717PubMedGoogle Scholar
  31. 31.
    Davies DM, Cavanagh J (1967) Jaundice from potassium p-aminobenzoate. Lancet 1:896PubMedGoogle Scholar
  32. 32.
    Luparini R, Rotundo A, Mattace R, Marigliano V (2000) Possibly ranitidine-induced autoimmune hepatitis. Ann Ital Med Int 15:214–217PubMedGoogle Scholar
  33. 33.
    Hullar TE, Sapers BL, Ridker PM, Jenkins RL, Huth TS, Farraye FA (1999) Herbal toxicity and fatal hepatic failure. Am J Med 106:267–268PubMedGoogle Scholar
  34. 34.
    Hollifield RD, Harbige LS, Pham-Dinh D, Sharief MK (2003) Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 36:133–141PubMedGoogle Scholar
  35. 35.
    Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M (1998) Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 50:570–571PubMedGoogle Scholar
  36. 36.
    Yoshida EM, Rasmussen SL, Steinbrecher UP, Erb SR, Scudamore CH, Chung SW, Oger JJ, Hashimoto SA (2001) Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 56:1416Google Scholar
  37. 37.
    Francis GS, Grumser Y, Alteri E, Micaleff A, O’Brien F, Alsop J, Moraga MS, Kaplowitz N (2003) Hepatic Reactions during treatment of Multiple Sclerosis with Interferon-beta-1a. Drug Safety 26:815–827PubMedGoogle Scholar
  38. 38.
    Duchini A (2002) Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 97:767–768PubMedGoogle Scholar
  39. 39.
    Jacobs LD, The Multiple Sclerosis Collaborative Research Group (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294PubMedGoogle Scholar
  40. 40.
    PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–15041PubMedGoogle Scholar
  41. 41.
    Tremlett H, Yoshida EM, Oger J (2004) Liver injury associated with the Beta-Interferons for MS: a comparison between the three products. Neurology 62:628–63PubMedGoogle Scholar
  42. 42.
    Benichou C, CIOMS (1990) Criteria of drug-induced liver disorders. J Hepatol 11:272–276PubMedGoogle Scholar
  43. 43.
    Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169–178PubMedGoogle Scholar
  44. 44.
    Nosaka K, Sakamoto K (1999) Changes in plasma enzyme activity after intramuscular injection of bupivacaine into the human biceps brachii. Acta Physiol Scand 167:259–265PubMedGoogle Scholar
  45. 45.
    Perry MC (1992) Chemotherapeutic agents and heptotoxicity. Sem Oncol 19:551–565Google Scholar
  46. 46.
    Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW (1993) Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplasic syndromes. Am J Clin Oncol 16:159–163PubMedGoogle Scholar
  47. 47.
    Fujimore K, Mochida S, Matsui A, Ohno A, Fujiwara K (2002) Possible mechanisms of elevation of serum transaminase levels during interferonbeta therapy in chronic hepatitis C patients. J Gastroenterol 37:40–46PubMedGoogle Scholar
  48. 48.
    Kellokumpu-Lehtinen P, Iisalo E, Nordman E (1989) Hepatotoxicity of paracetamol in combination with interferon and vinblastine. Lancet 1:1143Google Scholar
  49. 49.
    Fabris P, Palma MD, de Lalla F (2001) Idiosyncratic acute hepatitis caused by paracetamol in two patients with melanoma treated with high-dose interferon-alpha. Ann Intern Med 134:345Google Scholar
  50. 50.
    Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C (2002) Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 249:50–56PubMedGoogle Scholar
  51. 51.
    Lee WM (2003) Drug-induced Hepatotoxicity. N Engl J Med 349:474–485PubMedGoogle Scholar
  52. 52.
    Sena A, Pedrosa R, Ferret-Sena V, Almeida R, Andrade ML, Morais MG, Couderc R (2000) Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis. Clin Chem Lab Med 38:209–213PubMedGoogle Scholar
  53. 53.
    Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH (1992) The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 12:1053–1062PubMedGoogle Scholar
  54. 54.
    Rosenzweig IB, Wiebe DA, Borden EC, Storer B, Shrago ES (1987) Plasma lipoprotein changes in humans induced by beta-interferon. Atherosclerosis 67:261–267PubMedGoogle Scholar
  55. 55.
    Amacher DE (1998) Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 27:119–130PubMedGoogle Scholar
  56. 56.
    Anonymous (2003) Common Terminology Criteria for Adverse Events, National Cancer Institute. Cancer Therapy Evaluation Program. http://ctep.cancer.gov/reporting/ctc.html (Accessed 10 July, 2003)Google Scholar
  57. 57.
    Wang CS, Wang ST, Chang TT, Yao WJ, Chou P (2002) Smoking and Alanine Aminotransferase Levels in Hepatitis C Virus Infection. Arch Intern Med 162:811–815PubMedGoogle Scholar
  58. 58.
    The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661PubMedGoogle Scholar
  59. 59.
    Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M (2001) Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 57:1363–1370PubMedGoogle Scholar

Copyright information

© Steinkopff Verlag 2004

Authors and Affiliations

  1. 1.Department of Medicine (Neurology) rm S159Vancouver Hospital and Health Sciences Centre, University of British ColumbiaVancouver, BC, V6T 2B5Canada

Personalised recommendations